Insight Companies

HIV Drugs Market Overview Leading Companies and Innovations


HIV Medications Market Forecast Growth and Key Insights (2024 – 2032)

The HIV medications market is projected to expand from USD 33.32 billion in 2023 to over USD 49.68 billion by 2032, with a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032.

Advancements in HIV Treatment Improving Lives for Those with HIV

Researchers are continuously working to find better ways to treat HIV, leading to the development of new and more effective medications. These advances are helping people with HIV live healthier lives.

For example:

  • In April 2021, IAVI and Scripps Research announced the successful completion of a Phase I clinical trial for a new HIV vaccine.
  • In December 2021, ViiV Healthcare introduced Apretude, an FDA-approved medication designed to prevent sexually acquired HIV-1 infection. Apretude is a long-acting injectable form of pre-exposure prophylaxis (PrEP), offering an alternative to daily pills.

One of the key areas of progress is the development of innovative drug delivery systems. These systems ensure that medications reach the right areas of the body more efficiently. For instance, some treatments are now available as long-acting injections that only need to be administered once a month, rather than daily.

Key Companies in the HIV Drugs Market

Several major companies are leading the development and distribution of HIV medications. These companies are known for their significant contributions to the treatment and prevention of HIV:

  • ViiV Healthcare: A global leader in HIV treatment, ViiV Healthcare focuses on developing innovative therapies for people living with HIV.
  • Gilead Sciences, Inc.: Known for its pioneering work in HIV treatment, Gilead is one of the largest pharmaceutical companies producing antiretroviral medications.
  • Janssen Pharmaceuticals, Inc.: A part of Johnson & Johnson, Janssen Pharmaceuticals is committed to providing solutions for HIV care through cutting-edge medications.
  • F. Hoffmann-La Roche Ltd.: Roche is a global healthcare company that has developed several key HIV drugs, focusing on improving patient outcomes and advancing HIV research.
  • Mylan Pharmaceuticals Inc.: Known for its affordable generic medications, Mylan offers various HIV treatment options, making them accessible to a broader range of patients.
  • Theratechnologies Inc.: A biotechnology company, Theratechnologies specializes in developing therapies for HIV and other serious diseases, with an emphasis on improving quality of life for patients.
  • Boehringer Ingelheim International GmbH: This pharmaceutical giant focuses on discovering, developing, and bringing innovative HIV treatments to market.
  • Cipla Ltd.: An Indian multinational, Cipla is known for offering high-quality, cost-effective HIV drugs, making significant strides in improving access to treatment worldwide.
  • Teva Pharmaceutical Industries Ltd.: Teva is a global leader in generic and specialty medicines, offering a wide range of HIV treatments for patients around the world.
  • Merck & Co., Inc.: A global healthcare company, Merck is known for its advanced HIV treatments and continues to lead the way in HIV research and drug development.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions:  https://www.towardshealthcare.com/table-of-content/hiv-drugs-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5131

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

 

Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Recent Posts

Kedrion Biopharma’s COAGADEX® Receives FDA Orphan Drug Designation for Acquired Factor X Deficiency (AFXD)

Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More

17 hours ago

Benecard PBF and DecisionRX Join Forces to Personalize and Optimize Pharmacy Benefits

enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More

17 hours ago

Four Resilient Biotech Companies Making Waves in a Challenging Market

In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More

17 hours ago

Natera Launches TEODOR Trial in Partnership with ABCSG to Advance Personalized Breast Cancer Treatment

cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More

17 hours ago

Interventional Radiology Market: Size, Growth, and Leading Companies Driving Innovation

The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More

21 hours ago

Physical Therapy Market Growth and Leading Companies Driving Innovation

The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More

22 hours ago